Johannes Christian
Colorectal Cancer (CRC) remains a significant global health burden, necessitating the development of novel therapeutic strategies. The PI3K/Akt/ mTOR signaling pathway has emerged as a promising target in CRC due to its pivotal role in regulating cell proliferation, survival, and metabolism. This article provides a comprehensive overview of the dysregulation of the PI3K/Akt/mTOR pathway in CRC and discusses the therapeutic potential of targeting this pathway for CRC treatment. We explore the preclinical and clinical evidence supporting the efficacy of PI3K/Akt/mTOR inhibitors in CRC, highlighting ongoing challenges and future directions in harnessing this pathway for improved patient outcomes.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 